Press Room

Event

13th American DDF Summit - Drug Delivery & Formulation

Start
Monday, September 18, 2023 - 00:00
End
Tuesday, September 19, 2023 - 00:00
Location: Boston, USA
Booth Number: Table #13
Hovione present at DDF Summit USA 2023 in Boston | Hovione

Hovione will be exhibiting at DDF - American Drug Delivery & Formulation Summit - from 18 to 19 September in Boston, USA. The 2023 Summit covers innovative solutions to the greatest challenges in pharmaceutical, biologics and device development.

Don’t miss the chance to speak with our experts – Table #13 – and learn more about Epidel™ an innovative technology with the ability to deliver sustained-release pharmaceuticals via surface erosion resulting in the ability to precisely tune pharmacokinetics to meet the target indication needs.
 

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

 

HOVIONE PRESENTATION

On Sep. 19th do not miss the Technology & Innovation” session: "Controlled and sustained drug delivery - How Epidel™ is changing long-acting drug development"

Márcio Temtem and Ian Parrag will present and share how this simplified pro-drug synthetic approach is being used to fine-tune the delivery of drugs with higher drug loads, precise dosing, and prolonged therapeutic effect.

Marcio Temtem | Hovione

Márcio Temtem
Senior Director, Strategic Business Management Products at Hovione

Chemical engineer with 15 years of experience in the Pharmaceutical Industry, in the fields of Solubility Enhancement, Dry Powder Inhalation, Controlled Release, and Drug Product Development. 

Twelve years of experience in R&D, from which the last 2 years were heading Hovione’s team in Portugal, Reporting to Hovione's Chief Technology Officer, with responsibilities over Process Chemistry Development, Drug Product Development, Analytical Development, Process Safety, Modelling, and PAT.

In the last 2.5 years, Senior Director and Strategic Business Management Products, Reporting to Hovione's CEO, with responsibilities for the P&L and Development of the Portfolio of Products at Hovione.
Ian Parrag - Ripple | Hovione

Ian Parrag
Vice President of R&D at Ripple Therapeutics

Ian is one of the founders of Ripple Therapeutics (RIPL) following its spin out from Interface Biologics (IBI) in 2020. Ian has a PhD in Chemical and Biomedical Engineering from the University of Toronto and a BASc in Biomedical Engineering (Engineering Science) from the University of Toronto.

Ian joined IBI in 2010 and is responsible for leading the R&D Team in the discovery of novel prodrugs for drug delivery and in managing the nonclinical development (Preclinical evaluation and Chemistry, Manufacturing, and Controls (CMC)) for controlled drug delivery product concepts through to clinical readiness. As lead inventor for the EpidelTM technology, Ian is also responsible for managing and strategically developing Ripple’s platform and patent portfolio. Ian has 7 granted US patents, 11 pending US patent applications, 3 pending PCT patent application and 24 pending international patent applications along with a robust pipeline of provisional patent applications in process. Ian is an author of 7 peer-reviewed journal articles and recipient of a Natural Sciences and Engineering Research Council of Canada Industrial R&D Fellowship.

 

Get to know more about Epidel™  

 

 

Let’s discuss your project together. Schedule a meeting with our experts.

Find more about the 13th American DDF Summit - Drug Delivery & Formulation.

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All